Immune Cell-mediated Venous Thrombus Resolution

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2024 Jan 9

PMID 38193054

Authors

Peter K Henke

John M Nicklas

Andrea Obi

Affiliations

Soon will be listed here.

Abstract

Herein, we review the current processes that govern experimental deep vein thrombus (DVT) resolution. How the human DVT resolves at the molecular and cellular level is not well known due to limited specimen availability. Experimentally, the thrombus resolution resembles wound healing, with early neutrophil-mediated actions followed by monocyte/macrophage-mediated events, including neovascularization, fibrinolysis, and eventually collagen replacement. Potential therapeutic targets are described, and coupling with site-directed approaches to mitigate off-target effects is the long-term goal. Similarly, timing of adjunctive agents to accelerate DVT resolution is an area that is only starting to be considered. There is much critical research that is needed in this area.

Citing Articles

Bioinformatics-based discovery of biomarkers and immunoinflammatory infiltrates in hip fractures complicating deep vein thrombosis: A STROBE.

Fu Z, Song C, Mei Y, Zhou D, Zhou Y, Chen J Medicine (Baltimore). 2025; 103(52):e40809.

PMID: 39969342 PMC: 11688061. DOI: 10.1097/MD.0000000000040809.

MiR-497-5p Ameliorates Deep Venous Thrombosis by Facilitating Endothelial Progenitor Cell Migration and Angiogenesis by Regulating LITAF.

Xu S, Yang Z, Li L, Cui Y, Chen Z Biochem Genet. 2024; .

PMID: 39432130 DOI: 10.1007/s10528-024-10927-x.

Monocyte/macrophage-mediated venous thrombus resolution.

Lu M, Zhang J, Nie Z, Yan T, Cao Y, Zhang L Front Immunol. 2024; 15:1429523.

PMID: 39100675 PMC: 11297357. DOI: 10.3389/fimmu.2024.1429523.

Association Between Heart Rate at Diagnosis and Long-Term Recurrence Risk of Pulmonary Embolism in a Historical Cohort Study of Elder Women.

Li Y, Li F, Li M, Yi Q, Wu S Clin Appl Thromb Hemost. 2024; 30:10760296241268432.

PMID: 39056293 PMC: 11394350. DOI: 10.1177/10760296241268432.

References

Weitz J, Leslie B, Hirsh J, Klement P . Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest. 1993; 91(4):1343-50. PMC: 288105. DOI: 10.1172/JCI116335. View

Obi A, Andraska E, Kanthi Y, Kessinger C, Elfline M, Luke C . Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia. Thromb Haemost. 2016; 117(2):339-348. PMC: 5436925. DOI: 10.1160/TH16-03-0218. View

Kimball A, Schaller M, Joshi A, Davis F, DenDekker A, Boniakowski A . Ly6C Blood Monocyte/Macrophage Drive Chronic Inflammation and Impair Wound Healing in Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2018; 38(5):1102-1114. PMC: 5920725. DOI: 10.1161/ATVBAHA.118.310703. View

Alias S, Redwan B, Panzenboeck A, Winter M, Schubert U, Voswinckel R . Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2014; 34(4):810-819. PMC: 4728746. DOI: 10.1161/ATVBAHA.113.302991. View

Welsh J, Hoofnagle M, Bamezai S, Oxendine M, Lim L, Hall J . Hemodynamic regulation of perivalvular endothelial gene expression prevents deep venous thrombosis. J Clin Invest. 2019; 129(12):5489-5500. PMC: 6877343. DOI: 10.1172/JCI124791. View

Li W, Kessinger C, Orii M, Lee H, Wang L, Weinberg I . Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects. Circulation. 2021; 143(12):1224-1238. PMC: 7988304. DOI: 10.1161/CIRCULATIONAHA.120.049096. View

Mosevoll K, Lindas R, Anderson Tvedt T, Bruserud O, Reikvam H . Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. Thromb Res. 2015; 136(1):30-9. DOI: 10.1016/j.thromres.2015.04.002. View

Rectenwald J, Myers Jr D, Hawley A, Longo C, Henke P, Guire K . D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2006; 94(6):1312-7. DOI: 10.1160/TH05-06-0426. View

Lertkiatmongkol P, Liao D, Mei H, Hu Y, Newman P . Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol. 2016; 23(3):253-9. PMC: 4986701. DOI: 10.1097/MOH.0000000000000239. View

10.

Rabinovich A, Cohen J, Cushman M, Wells P, Rodger M, Kovacs M . Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. J Thromb Haemost. 2014; 13(3):398-408. DOI: 10.1111/jth.12814. View

11.

Meznarich J, Malchodi L, Helterline D, Ramsey S, Bertko K, Plummer T . Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. PLoS One. 2013; 8(3):e57837. PMC: 3594198. DOI: 10.1371/journal.pone.0057837. View

12.

Culmer D, Dunbar M, Hawley A, Sood S, Sigler R, Henke P . E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model. Thromb Haemost. 2017; 117(6):1171-1181. DOI: 10.1160/TH16-04-0323. View

13.

Alias S, Lang I . Coagulation and the vessel wall in pulmonary embolism. Pulm Circ. 2014; 3(4):728-38. PMC: 4070824. DOI: 10.1086/674768. View

14.

San Norberto E, Gastambide M, Taylor J, Garcia-Saiz I, Vaquero C . Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis. Vasa. 2016; 45(2):133-40. DOI: 10.1024/0301-1526/a000507. View

15.

Streiff M, Agnelli G, Connors J, Crowther M, Eichinger S, Lopes R . Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016; 41(1):32-67. PMC: 4715858. DOI: 10.1007/s11239-015-1317-0. View

16.

Dougherty K, Pearson J, Yang A, Westrick R, Baker M, Ginsburg D . The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A. 1999; 96(2):686-91. PMC: 15197. DOI: 10.1073/pnas.96.2.686. View

17.

Reinke A, Li S, Warnock M, Shaydakov M, Guntaka N, Su E . Dual-reporter high-throughput screen for small-molecule inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate. J Biol Chem. 2018; 294(5):1464-1477. PMC: 6364767. DOI: 10.1074/jbc.RA118.004885. View

18.

Diaz J, Obi A, Myers Jr D, Wrobleski S, Henke P, Mackman N . Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol. 2012; 32(3):556-62. PMC: 3292052. DOI: 10.1161/ATVBAHA.111.244608. View

19.

Metz A, Luke C, Dowling A, Henke P . Acute experimental venous thrombosis impairs venous relaxation but not contraction. J Vasc Surg. 2019; 71(3):1006-1012.e1. PMC: 6928442. DOI: 10.1016/j.jvs.2019.03.064. View

20.

Baxi S, Crandall D, Meier T, Wrobleski S, Hawley A, Farris D . Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis. Thromb Haemost. 2008; 99(4):749-58. DOI: 10.1160/TH07-11-0669. View